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Abstract
Background:  Treatment of osteomyelitis often requires antibiotics over an extended period. 
Underinsured patients are often kept in an acute care setting for the duration of treatment
rather than a subacute care facility or at home for antibiotic administration due to difficulties
with placement in lower-level care settings.  This provides a significant financial burden on
both the hospitalized patient and the hospital system.  This report highlights the wide
discrepancy between costs to the patient between care settings.
Methods:  A theoretical patient scenario based on a current patient scenario was described to
billing officers at a large tertiary care center with affiliated extended care facilities and home
healthcare services.  Costs to the patient for antibiotics, as well as room and board were
obtained.
Findings:  Six weeks of inpatient care with dual-therapy broad-spectrum antibiotics and basic
nursing care costs $50,980.  Similar care at an extended care facility costs $31,072, while
similar services provided by home health nursing costs $12,307.
Conclusions:  The uninsured patient population is placed with a large financial burden when
undergoing long-term antibiotic treatment.  Practitioners and care coordinators should evaluate
the proper setting for treatment for patients on an individual basis and strive to find appropriate
placement amidst financial challenges.  Charitable care that provides medications and
potentially other medical needs at a reduced rate for patients with limited financial resources
and no insurance should be considered. These efforts will reduce the cost of treatment to the
patient and in turn reduce the burden on the hospital system.
Background:
Due to the complexity and diversity of patient health issues, there is little recent literature
analyzing the cost of inpatient versus outpatient care for patients with osteomyelitis who are
otherwise medically stable.  Osteomyelitis, without other systemic symptoms, typically requires
at least 4 weeks of parenteral antibiotics (1). Patients who are under- or uninsured, often
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remain in an acute-care setting for longer periods than necessary since they have limited or no
funding for home health or medical equipment.  Furthermore, many private nursing facilities
and rehabilitation centers have limited funding to accept these patients, leading to prolonged
hospitalization and difficulty in coordinating post-hospital care (2).
Despite federal mandates that patients are required to purchase insurance, 13% of patients
ages 18-64, decreased from 18.4% in 2013. Additionally, 18% of adults are covered by
government insurance, which has the lowest reimbursement rate to hospitals and care facilities
(3). Given that average hospital reimbursement rates are approximately 15%, and Midwest
hospitals write off 11.4% of total gross revenue as “uncollectable” (4), it is surprising that long
hospitalizations solely for intravenous (IV) antibiotics continue to occur.
Recent media highlights the fact that new policy holders under the Affordable Care Act are
sicker and costlier to insurers than predicted, leading to more hospital admissions, physician
visits, and insurance claims (5). With increased demand on hospital systems and payers, and
financial challenges for these patients, healthcare workers should be aware of costs and
burdens associated with prescribed care and make attempts to minimize them when possible.
Grayson, et al analyzed 20 patients  – 10 with osteomyelitis, 5 with endocarditis, 4 with
vascular graft or pacemaker sepsis, and 1 with chronic cellulitis –   and found a cost reduction
of $112 per day over the 538 days of combined care when comparing inpatient stay versus
home healthcare (6). Nursing care was delivered daily and included initial assessment and a
30 minute visit as well as dressings and other consumable medical supplies.  In this study,
home treatment was well-tolerated and cure was achieved in 18 of the patients.  Payment of
hospital overhead, salaried positions, and ancillary staff were thought to be the primary
difference in cost.
Milkovich also demonstrated significant cost savings and benefits of home IV antibiotic therapy
over hospital-based care (7-8). Increased mobility in patients undergoing home treatment
improved quality of life and increased productivity.  Patients who are able to return to work or
daily activities will also have the benefit of maintaining an income during their treatment
course, which would not be possible while hospitalized.
The purpose of this study is to determine the overall cost for patients undergoing a 6-week
treatment of IV Vancomycin and Cefepime for osteomyelitis in the inpatient or outpatient
setting.  Bringing this information to light will help practitioners, care coordinators, and hospital
administrators eliminate unnecessary costs to the patient and health system.
Methods:
A theoretical patient scenario based on a representative patient under our care was described
to financial and billing officers at a large tertiary care center with affiliated extended care facility
and home health service.  The scenario involved:
“A 45 year old otherwise healthy and ambulatory male with mandibular osteomyelitis required
removal of hardware by the plastic surgery team.  The patient has a 2cm superficial wound
from operative debridement requiring daily wound checks.  The patient is stable and ready for
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discharge by post-operative day 2.  Infectious disease has recommended 6 further weeks of IV
Vancomycin (1g IV q12h) and Cefepime (2g IV q12h) for broad spectrum coverage.”
Each setting was asked to describe costs incurred during the care of that patient, including
room cost, nursing care, laboratory costs, and IV infusions.  Once data were received from
each source, costs were then evaluated and compared via a detailed economic analysis. 
Vancomycin and cefepime are a common antibiotic regimen at our institution for chronic
osteomyelitis, although any medication could be input into this model.  All costs were collected
from our large, 1,176 bed tertiary care center with associated 120 bed extended care facility,
and home health company that made 201,240 visits in 2014.  Costs were collected and
reported in 2015 US dollars.
Results:
In the inpatient setting, financial officers describe little variability in cost of care or flexibility in
charges.  Given that the majority of these patients require a private room due to length of stay
and presence of multiple or resistant bacteria, costs for this setting of care were used.  An
inpatient private room with nursing care costs $949 per day, compared to a private room at an
extended care facility, which costs $475 per day.   In both settings, this includes cost of the
room, basic necessities for daily hygiene such as soap, tissue products, linen services, and a
regular diet.  It also includes the cost of daily nursing care – including vital sign monitoring,
dressing changes as ordered by the physician, patient hygiene care, and any other prescribed
tasks – by a single nurse and nursing assistant if a nurse is caring for more than 4 patients
simultaneously.  This does not include cost of specialty dressing supplies or physician fees. 
 Inpatient laboratory tests – complete blood count, basic metabolic panel, erythrocyte
sedimentation rate, c-reactive protein, and vancomycin trough – cost $740, but are discounted
40% to $440 for patients who are self-pay (Table 1).   For this analysis, we assume weekly
laboratory testing, which is conservative.  Actual cost differences between care settings would
increase with more frequent testing.
Table 1. Cost of laboratory tests typically ordered for patients with chronic infection. Reported
as charge to the patient in our healthcare system.
Inpatient and Extended Care Facility* Home Health Care
Complete Blood Count $87.60 $40.56
Basic Metabolic Panel $133.80 $50.08
Erythrocyte Sedimentation Rate $39.60 $35.69
C-Reactive Protein $72.00 $72.47
Vancomycin trough $111 $135.20
Total $444.00 $334.00
*Rates reflect direct charge to a self-pay patient, which is discounted 40% from rates charge to
insurance companies, or $740.00.
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Home care nursing visits cost $100 per visit and include antibiotic infusion, wound checks, and
dressing changes.  When possible, nurses teach patients or family to infuse antibiotics, limiting
visits to once per day or as needed. Our home healthcare service receives antibiotics from an
outpatient supplier and is able to charge slightly less due to this.  Individually, antibiotics are
$41.46 per dose for vancomycin and $41.20 per dose for cefepime.  However, if patients
receive more than one antibiotic per day with our home health care service, the antibiotic with
lesser cost is given at a $20 per day discount.   Laboratory tests are most commonly sent to a
private laboratory contracted through the home health company, and these costs are also
displayed in Table 1.   Prices were calculated based on daily home visits, although in reality
this will vary between patients from once weekly to twice daily, with cost remaining $100/visit.
Inpatient and extended care facility antibiotics are received from the same pharmacy within our
system, and therefore have the same associated cost.  Hospital cost, or wholesale acquisition
cost, of these antibiotics at our institution is $2.65 per dose for vancomycin, and $3.55 per
dose for cefepime.  The associated mark-up presented in Table 2 is the patient charge.
 Laboratory tests at the extended care facility are also processed in the hospital laboratory so
have an identical cost.
Total cost for a 6 week inpatient stay was $50,980.80.  A similar stay at an extended care
facility was $31,072.8, and 6 weeks of outpatient nursing care, weekly laboratory testing, and
daily home antibiotic infusion was $12,307.  This is an overall cost reduction of $19,908.00 for
an extended care setting and $38,673.36 for care in an outpatient setting.
Lastly, our extended care facility does have a charity program for a select number of patients
per year based on income and assets with respect to the Federal Poverty Guidelines (9) and
family size.  If a patient is uninsured or “private pay” their financial situation is closely analyzed
by administrators. If they are deemed to qualify, their room rate is reduced to $250 per day,
and antibiotics are given at hospital cost plus an additional 10%, or $2.91 per dose for
vancomycin and $3.90 for cefepime.  Unfortunately, we were not able to find details regarding
the number of patients able to accepted into this program, nor acquire exact criteria for this
decision for purposes of this study, as decisions are made on a case-by-case basis and vary
by year.  Total cost for this stay is $13,736, similar in cost to outpatient home care in our
system.
Table 2 summarizes the cost for 6 weeks of care requiring nursing care, laboratory monitoring,
and parenteral duel antibiotic treatment for broad spectrum coverage.
Table 2. Costs of care for a six week period. Costs reported as charge to the patient in our
healthcare system. Laboratory assumes weekly CBC, BMP, ESR, CRP, and vancomycin
trough. Nursing care includes routine vital signs, wound care and medications prescribed by
the physician, and patient hygiene. Laboratory testing includes tests in Table 1.
Setting Room +
Nursing Cost
(per day)
IV Vancomycin
(per dose)
IV Cefepime
(per dose)
Laboratory
testing
(per week)
Six week
total
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Inpatient $949 $43.20 $57.50 $444.00 $50980.80
Extended Care
Facility
$475 $43.20 $57.50 $444.00 $31072.80
Extended Care
Charity Program*
$250 $2.91 $3.90 $444.00 $13736.04
Home Health Care $100 $41.46 $31.20 $334.00 $12307.44
*May be subsidized in specific “private pay” patients for $250/d after analysis of resources,
which reduces daily cost to $263.66 or a 6 week total of $11,073.72. Qualifications based on
US Federal Poverty Guidelines (9).
Discussion:
Cost of medical care continues to increase, as does the number of patients who are insured
via government programs, such as Medicaid (3). Fortunately, there are fewer uninsured
patients, with the initiation of the Affordable Care Act (ACA), but this has caused an increased
burden on the hospital system and insurance companies with increased accessibility to care. 
In 2012, prior to the ACA, 75 million people reported difficulty paying off medical bills or paying
off medical debt; this is a rise from 58 million in 2005 (4). While this may decrease with recent
changes in coverage, more patients will be seeking healthcare, so pressures to control cost
will remain for physicians and hospital systems.  With this in mind, hospitals and providers are
searching for solutions to reduce the debt burden on patients and the system.
The patient scenario given to three different healthcare settings led to substantial cost
differences, and these are not surprising.  Charge to an uninsured or self-pay patient for a 6
week inpatient stay is $50,981.  There are instances, such as systemic illness, concomitant
comorbidities, unsafe home environment, or lack of social support, when an inpatient stay is
appropriate and these costs may be justified.  Furthermore, patients with a history of IV drug
abuse, prior catheter-related infections, or in an immunocompromised state may be unable to
receive a long-term IV catheter and may not meet criteria for discharge.   However, given that a
subacute monitored care setting, such as an extended care facility may charge only half the
rate of an acute care hospital, this option should be pursued aggressively by hospital
administrators, care coordinators, and healthcare providers.  In our system, if a patient meets
standards applied by financial officers, the extended care facility may be able to reduce this
cost by another 50%, reducing the financial burden on the patient to $13,736 (Table 2).
Finally, if a patient is deemed a candidate for outpatient care and has the appropriate social
support and home environment, this option is most financially feasible at $12,307.  In addition,
the patient may continue to work, care for dependents, and participate in daily activities as
deemed appropriate, further reducing overall costs of the illness by maintaining income.  For
many patients, home care is appropriate and they may be discharged with long-term IV
access, such as a PICC line.  However, as previously stated, for some patients we recognize
that home care is not always a viable option.  Similarly, not all patients will be able to be
properly educated on infusion, and will require more visits than modeled in this study.
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For patients who remain uninsured, Medicaid expansion and Marketplace enrollment have
streamlined the application process, increased eligibility, and made health insurance more
affordable as a whole (10). While rates of uninsured patients are declining because of these
changes, there is still a large number of patients who are paying out of pocket for medical care
and require creative discharge planning.  Care coordinators should work towards assisting
these patients in finding health care coverage when possible to minimize the financial impact
on the patient and the healthcare system, and if possible gain placement in an extended care
facility if still needed.
We recommend that hospital systems, when able, consolidate the care for medially stable
patients requiring IV antibiotics whose care needs or high risk social situation are unsafe for
discharge home into an extended care facility or nursing ward with reduced overhead cost.
This will improve the financial burden on the hospital system and the patient. In addition, for
patients with limited financial resources and no insurance, charitable or reduced cost care
should be considered. Hospital systems can develop a metric to identify qualified patients and
provide care and medications at a lower rate. Because charitable care is often assumed in
some of this patient population because of an inability to pay high medical bills, it makes sense
to reduce the financial burden on the patient as well.
Another potential option for hospital systems that do not have a charity system or associated
subacute care facility or home health system would be to contract with private organizations to
create a streamlined process of discharging patients to more appropriate levels of care while
minimizing the cost to both facilities.
The main limitation of this study is that the data and financial figures are theoretical data from a
single institution.  Lack of described comorbidities is another limitation, however for simplicity
of the model, osteomyelitis without systemic manifestations was described.  Furthermore,
while this case was described as 6 weeks of antibiotic treatment post-discharge, it does not
take into account the inpatient care that precedes this decision, which will vary by patient. 
Finally, not all patients with osteomyelitis will require a full 6 weeks of parenteral antibiotics,
and may be treated with oral antibiotic therapy, allowing for earlier discharge from an acute
care setting.  A directed effort to identify causative pathogens with the goal of narrowing
antibiotic coverage should always be encouraged and cultures should be obtained prior to the
initiation of antibiotics in stable patients whenever possible.
In spite of these limitations, the data presented here are applicable to current practice, as cost
savings are exemplified in this simplified scenario.  This study also serves as a model for a
future prospective analysis using patient information and billing data, and may be used by
hospital systems to understand the financial impact of our recommendations or other attempts
to safely reduce cost.
In conclusion, inpatient care is unsurprisingly the most expensive of all care settings, with a 6
week cost of over $50,000.  Cost to the patient may be reduced by nearly half when patients
are placed into extended care facilities, and quartered if they are candidates for home care
and home infusion.  Because of costs and morbidities associated with prolonged antibiotic
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therapy, physicians should confirm osteomyelitis and obtain sufficient cultures via bone biopsy
prior to initiation of antibiotic care in stable patients.  Safe options to shorten the duration of
parenteral therapy or use of oral therapy should be discussed with infectious disease
colleagues.  Social workers, hospital administrators, and healthcare providers should strive to
place these patients into the lowest-cost setting when possible.  It may be in an institution’s
interest to open a hospital ward or make arrangements with extended care facilities with lower
overhead.  Because charges billed to an uninsured patient with limited financial resources are
less likely to be paid, institutions should develop criteria for identifying patients who can
receive medications or other care at a reduced rate to reduce the burden on those patients.
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